Shanghai Fosun Pharmaceutical (Group) Co.'s (HKG:2196) independently developed small molecule oral DPP-1 inhibitor, XH-S004, has been approved for clinical trials in China for the treatment of chronic obstructive pulmonary disease (COPD).
XH-S004 is also being trialed for the treatment of non-cystic fibrosis bronchiectasis, according to its Hong Kong bourse filing on Friday.
As of April, the Group had invested about 61 million yuan in the research and development of XH-S004.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.